Blog
RSS FeedPosted by Michael Wonder on 17 Mar 2019
On the use of list prices in drug pricing research
14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...
Posted by Michael Wonder on 15 Mar 2019
PBAC Public Summary Documents - November 2018 meeting (rejections and deferrals)
15 March 2019 - The Public Summary Documents (first time rejections and deferrals) from the November 2018 PBAC meeting are now ...
Posted by Michael Wonder on 15 Mar 2019
Health Canada begins release of clinical data on drugs and devices
14 March 2019 - Health Canada launched two public databases on Wednesday as the first step in making clinical information ...
Posted by Michael Wonder on 14 Mar 2019
CMS updates drug dashboards with prescription drug pricing and spending data
14 March 2019 - Dashboards further the agency’s efforts to increase price transparency throughout the healthcare system and create incentives ...
Posted by Michael Wonder on 12 Mar 2019
Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates
12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...
Posted by Michael Wonder on 08 Mar 2019
Direct-acting anti-virals for hepatitis C - outcome statement
8 March 2019 - The outcome statement for the direct-acting anti-virals for hepatitis C stakeholder meeting held on 13 December 2018 ...
Posted by Michael Wonder on 01 Mar 2019
PBAC public summary documents - November 2018 meeting
1 March 2019 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the November 2018 PBAC ...
Posted by Michael Wonder on 27 Feb 2019
EMA publishes agenda for 25-28 February 2019 CHMP meeting
25 February 2019 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 15 Feb 2019
FDA advances new efforts to promote development of safe and effective regenerative medicine products
15 February 2019 - Today, the FDA finalised two guidance documents regarding regenerative medicine therapies. ...
Posted by Michael Wonder on 14 Feb 2019
OIA responses: exploring ways to publish them
14 February 2019 - To support New Zealand's commitment to open government, PHARMAC is exploring ways to publish more of ...
Posted by Michael Wonder on 08 Feb 2019
J&J becomes first drug maker to add prices to television ads
8 February 2019 - Johnson & Johnson said on Thursday it will start adding the price of its medicines to ...
Posted by Michael Wonder on 29 Jan 2019
Identifying the need for good practices in health technology assessment-summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
26 January 2019 - The systematic use of evidence to inform healthcare decisions, particularly health technology assessment, has gained increased recognition. ...
Posted by Michael Wonder on 18 Jan 2019
2019 April price disclosure cycle – indicative prices
18 January 2019 - Indicative 1 April 2019 prices resulting from the 2019 April cycle of price disclosure have now been ...
Posted by Michael Wonder on 17 Jan 2019
FDA is urged to mandate disclosure of clinical trial summaries as pilot program stalls
16 January 2019 - One year after the FDA launched a voluntary pilot program to release clinical study reports, which ...
Posted by Michael Wonder on 14 Jan 2019
Revised guideline aims to strengthen global approach to development of new antibacterial medicines
14 January 2019 - EMA has published a PDF revision of its guideline on the evaluation of human medicines ...